Immunotherapy drug shows promise before colon cancer surgery
NCT ID NCT05116085
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug tislelizumab given before surgery in 33 people with early-stage colorectal cancer that has specific genetic changes (MSI-H or dMMR). The goal was to see if the drug could shrink or eliminate tumors before surgical removal. The trial has completed, and results will show how many patients had a major or complete response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tislelizumab (an immunotherapy drug given by IV)
What this could lead to
If successful, this could lead to a new treatment option that shrinks tumors before surgery, potentially improving outcomes for people with this specific type of colorectal cancer.
What could go wrong
This is a small, early-phase trial with only 33 participants, so results may not apply to everyone. The drug may cause side effects or not work as well in larger, more diverse groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
-
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, 110042, China
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
Sun Yat Sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The Affiliated Hospital of Qingdao University Branch South
Qingdao, Shandong, 266000, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, 233004, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China